Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling
Systemic immunity plays an important role in cancer immune surveillance and response to therapy, but little is known about the immune status of children with solid cancers. We performed a high-dimensional single-cell analysis of systemic immunity in 50 treatment-naive pediatric cancer patients, comparing them to age-matched healthy children. Children with cancer had a lower frequency of peripheral NK cells, which was not due to tumor sequestration, had lower surface levels of activating receptors and increased levels of the inhibitory NKG2A receptor. Furthermore, the natural killer (NK) cells of pediatric cancer patients were less mature and less cytotoxic when tested in vitro. Culture of these NK cells with interleukin-2 restored their cytotoxicity. Collectively, our data show that NK cells in pediatric cancer patients are impaired through multiple mechanisms and identify rational strategies to restore their functionality.
History
Publication
iScience, 20224, 27, (9)Publisher
ElsevierOther Funding information
This work was funded by the Cancer Research UK Birmingham Centre and Birmingham Children’s Hospital Charity (grant: BCHRF479). This work was supported in part by the European Regional Development Fund (no. CZ.02.1.01/0.0/0.0/16_019/0000868) and NIH / NCI grant R01 CA226833 (J.M.I. and S.M.L.).Also affiliated with
- Health Research Institute (HRI)
Sustainable development goals
- (3) Good Health and Well-being
- (6) Clean Water and Sanitation